DexCom’s (DXCM) Buy Rating Reiterated at Truist Financial

Truist Financial reaffirmed their buy rating on shares of DexCom (NASDAQ:DXCM) in a research note published on Tuesday morning,Benzinga reports. Truist Financial currently has a $80.00 price target on the medical device company’s stock, down from their previous price target of $82.00.

Other equities analysts have also issued reports about the company. BTIG Research reaffirmed a “buy” rating and set a $85.00 target price on shares of DexCom in a research report on Friday, February 13th. Piper Sandler restated an “overweight” rating on shares of DexCom in a research note on Thursday, February 5th. TD Cowen dropped their price objective on shares of DexCom from $100.00 to $84.00 and set a “buy” rating on the stock in a research note on Friday, October 31st. Morgan Stanley reiterated an “overweight” rating on shares of DexCom in a report on Monday, January 12th. Finally, Evercore initiated coverage on shares of DexCom in a report on Tuesday, November 25th. They issued an “in-line” rating and a $68.00 target price on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $85.18.

DexCom Stock Down 0.7%

DexCom stock opened at $72.27 on Tuesday. The company has a quick ratio of 1.59, a current ratio of 1.88 and a debt-to-equity ratio of 0.45. The company has a market capitalization of $27.81 billion, a PE ratio of 34.41, a PEG ratio of 1.42 and a beta of 1.49. The firm’s fifty day moving average is $69.37 and its 200 day moving average is $69.37. DexCom has a 12-month low of $54.11 and a 12-month high of $91.87.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Thursday, February 12th. The medical device company reported $0.68 earnings per share for the quarter, beating the consensus estimate of $0.65 by $0.03. The firm had revenue of $1.26 billion during the quarter, compared to the consensus estimate of $1.25 billion. DexCom had a net margin of 17.94% and a return on equity of 32.12%. The business’s revenue was up 13.1% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.45 earnings per share. As a group, sell-side analysts predict that DexCom will post 2.03 EPS for the current fiscal year.

Institutional Trading of DexCom

A number of institutional investors and hedge funds have recently modified their holdings of the business. Brighton Jones LLC increased its position in shares of DexCom by 257.7% during the 4th quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company’s stock valued at $1,290,000 after purchasing an additional 11,946 shares during the last quarter. Integrated Wealth Concepts LLC grew its position in DexCom by 6.3% during the first quarter. Integrated Wealth Concepts LLC now owns 3,329 shares of the medical device company’s stock valued at $227,000 after buying an additional 196 shares during the period. Empowered Funds LLC increased its holdings in DexCom by 5.4% during the first quarter. Empowered Funds LLC now owns 8,446 shares of the medical device company’s stock worth $577,000 after buying an additional 436 shares during the last quarter. Focus Partners Wealth raised its position in DexCom by 13.2% in the first quarter. Focus Partners Wealth now owns 7,218 shares of the medical device company’s stock worth $493,000 after acquiring an additional 841 shares during the period. Finally, Private Trust Co. NA boosted its stake in DexCom by 84.4% in the second quarter. Private Trust Co. NA now owns 1,239 shares of the medical device company’s stock valued at $108,000 after acquiring an additional 567 shares during the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.